Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable
development over recent decades. However, this field is currently in a state of flux toward niche-…

The anthracycline doxorubicin (Doxo) and its analogs daunorubicin (Daun), epirubicin (Epi),
and idarubicin (Ida) have been cornerstones of anticancer therapy for nearly five decades. …

Clinically relevant immunological biomarkers that discriminate between diverse hypofunctional
states of tumor-associated CD8 + T cells remain disputed. Using multiomics analysis of …

Immunogenic cell death (ICD) refers to an immunologically distinct process of regulated cell
death that activates, rather than suppresses, innate and adaptive immune responses. Such …

CE‐MS is applied in clinical proteomics for both the identification of biomarkers of disease
and assessment of biomarkers in clinical diagnosis. The analysis is reproducible, fast, and …

Acute myeloid leukemia (AML) is caused by genetic aberrations that also govern the prognosis
of patients and guide risk-adapted and targeted therapy. Genetic aberrations in AML are …

Tumour-associated macrophages (TAMs) are essential players in the tumour microenvironment
(TME) and modulate various pro-tumorigenic functions such as immunosuppression, …

Background Tumors can influence peripheral immune macroenvironment, thereby creating
opportunities for non-invasive serum/plasma immunobiomarkers for immunostratification and …

A genetic diagnosis of autosomal‐dominant polycystic kidney disease (ADPKD) is challenging
due to allelic heterogeneity, high GC content, and homology of the PKD1 gene with six …

Immune checkpoint blockers (ICBs)-based immunotherapy has revolutionised oncology.
However, the benefits of ICBs are limited to only a subset of patients. Herein, the biomarkers-…